VARIANT OF RARE HERMANSKY — PUDLAK SYNDROME ASSOCIATED WITH GRANULOMATOUS COLITIS: DIAGNOSTICS, CLINICAL COURSE AND TREATMENT

2018 ◽  
Vol 40 (1) ◽  
pp. 73-78 ◽  
Author(s):  
L Y Lozynska ◽  
A Plawski ◽  
M R Lozynska ◽  
I Vytvytskyi ◽  
R Y Lozynskyi ◽  
...  

Aim: To study the relationship between the genotype and the phenotype in the patients with Hermansky — Pudlak syndrome (HPS) associated with granulomatous colitis; to monitor clinical course of the disease for adequate treatment, cancer surveillance and genetic counseling. Materials and Methods: The diagnosis of HPS is established by physical examination, chest X-ray, computed tomography, endoscopic examination with biopsy, and laboratory tests, including histology, baseline laboratory blood, urine and feces tests, determination of ASCA-C and ANCA antibodies using an ELISA. Molecular genetic testing for HPS gene mutations, R702W, G908R, L1007fs and P268S mutations in NOD2 gene, and TaqI variant of the VDR gene were carried out. Results: We report 2 cases of HPS from unrelated families. Both were complicated by inflammatory bowel disease with pathologic features of Crohn’s disease refractory to antibiotics and corticosteroids. One patient (family 1) with Ashkenazi Jewish ancestry had pathogenic variant of the HPS-4 gene in exon 8, mutation P268S of NOD2 genes and “Tt” genotype of TaqI variant of the VDR gene. Another patient (family 2) carried two mutations P268S and G908R of NOD2 gene, and had a large paraovarian cyst diagnosed. No consistent success with the standard medical therapy, used for treating granulomatous colitis, associated with HPS, in presented cases was achieved. Patients needed surgical interventions at a young age and a long-term surveillance of the probable development of tumors and other complications. Azathioprine at 2 mg/kg/day and mesalazine 3 g/day were used with some positive effect for prevention of Crohn’s disease postoperative recurrence. Conclusion: The occurrence of perianal lesions, the histopathological findings and the results of the molecular genetic analysis confirmed the mutations P268S and G908R of NOD2 gene in these cases suggest that HPS was truly associated with Crohn’s disease variant with early onset and severe course. The search for the molecular causes of the disease in some individuals may help in the development of new therapeutic and surgical approaches, as well in the improvement of understanding of premalignant inflammatory conditions in a large bowel.

1995 ◽  
Vol 108 (4) ◽  
pp. A882 ◽  
Author(s):  
A. Musso ◽  
R. Sostegni ◽  
M. Astegiano ◽  
G. Rocca ◽  
M.T. Fiorentini ◽  
...  

2003 ◽  
Vol 124 (4) ◽  
pp. A376
Author(s):  
Vito Annese ◽  
Arnaldo Andreoli ◽  
Bollani Serafina ◽  
Fabiana Castiglione ◽  
Mario Cottone ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (11) ◽  
pp. e108503 ◽  
Author(s):  
Fabian Schnitzler ◽  
Matthias Friedrich ◽  
Christiane Wolf ◽  
Marianne Angelberger ◽  
Julia Diegelmann ◽  
...  

Author(s):  
Mathurin Fumery ◽  
Jean-Louis Dupas ◽  
Pierre Desreumaux

2011 ◽  
Vol 140 (5) ◽  
pp. S-792
Author(s):  
Zhaoxiu Liu ◽  
Haiyan Lu ◽  
Runzhou Ni ◽  
Pokala R. Kiran ◽  
Bo Shen

2021 ◽  
Vol 115 ◽  
pp. 106588
Author(s):  
Junzhang Zhao ◽  
Hongxing Han ◽  
Bu Zhong ◽  
Wenjing Xie ◽  
Ying Chen ◽  
...  

2019 ◽  
Vol 13 (Supplement_1) ◽  
pp. S188-S188
Author(s):  
J D Schulberg ◽  
E K Wright ◽  
B A Holt ◽  
T R Sutherland ◽  
S J Hume ◽  
...  

2013 ◽  
Vol 52 (4) ◽  
pp. 445-449 ◽  
Author(s):  
Mitsue Sogawa ◽  
Kenji Watanabe ◽  
Yutaro Egashira ◽  
Kiyoshi Maeda ◽  
Kenichi Morimoto ◽  
...  

1994 ◽  
Vol 29 (4) ◽  
pp. 406-414 ◽  
Author(s):  
Mitsuo Okada ◽  
Toshihiro Sakurai ◽  
Tsuneyoshi Yao ◽  
Mitsuo Iida ◽  
Nobuo Okabe ◽  
...  

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S107-S108
Author(s):  
J Rosh ◽  
D Turner ◽  
A Griffiths ◽  
D Jacobstein ◽  
O Adedokun ◽  
...  

Abstract Background Ustekinumab (UST) is approved for the treatment of adults with moderate to severe Crohn’s disease (CD). The objective of this study was to evaluate the pharmacokinetics (PK), safety, and efficacy of UST in paediatric patients with moderately to severely active CD who had failed treatment with corticosteroids (CS) and/or immunomodulators (IM) and/or anti-tumour necrosis factor (TNF) therapies. Here, we report the safety and efficacy results through Week 16; PK results are reported separately. Methods This was a Phase 1, multicentre, 16-week, double-blind induction dose-ranging study (NCT02968108) in patients aged 2 to <18 years (body weight [BW] ≥10 kg) with a Paediatric CD Activity Index (PCDAI) score >30 and at least an abnormal C-reactive protein >3.0 mg/l or faecal calprotectin >250 µg/g), or ulcerations in the ileum or colon upon ileocolonoscopy despite adequate treatment with CS ± IM ± anti-TNF therapy. Patients were randomised (1:1) and stratified by weight and prior anti-TNF use for induction to one of 2 weight range-based intravenous (IV) doses: 130mg vs. 390 mg if BW ≥40 kg and 3 mg/kg vs. 9 mg/kg if BW <40 kg. At week 8, all patients received a single subcutaneous (SC) UST maintenance dose of 90mg if BW ≥40 kg or 2 mg/kg if BW <40 kg. Results Forty-four patients (59% ≥40kg BW; >90% anti-TNF exposed) were randomised (n = 23 lower dose; n = 21 higher dose) and treated with UST. Baseline characteristics are summarised in Table 1. At week 16, in the lower dose and higher dose groups, 52%/52% achieved clinical response (reduction in PCDAI ≥15) and 22%/29% had clinical remission (PCDAI ≤10), respectively (Table 2). In addition, 32% and 28% of patients showed endoscopic response (reduction in Simple Endoscopic Score for CD of ≥50%), respectively. Through week 16, 73% of patients reported ≥1 adverse event (AE; 82.6% lower dose vs. 62% higher dose); 2 discontinued due to AEs (1 in each group). Serious AEs occurred in 16% of patients (26% lower dose and 5% higher dose, with CD exacerbation being the most frequent (13%/5%, respectively). Infections occurred in 41% of patients (1 was serious, which was intestinal abscess that spontaneously resolved with sequelae). No injection site reactions, opportunistic infections, malignancies, or deaths were reported. No antibodies to UST were observed. Conclusion As early as 3 weeks and through 16 weeks, both the lower and higher doses of UST (IV week 0 and SC at week 8) improved clinical and endoscopic disease activity in this previously treatment-refractory group of children with CD. The safety profile was consistent with that for UST in adults with CD.


Sign in / Sign up

Export Citation Format

Share Document